Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey.
Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Center for Blood, University of Health Sciences, Istanbul, Turkey.
Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):301-308. doi: 10.51821/85.2.9440.
Helicobacter pylori (Hp) and Epstein-Barr virus (EBV) are involved in gastric cancer (GC) etiology. EBV/Hp co- infection was thought synergistically increase gastroduodenal disease occurence. We aimed to determine the presence of EBV/Hp co-infection in gastroduodenal diseases.
The study group had 68 Hp (+) cases [25 GC, 13 IM (intestinal metaplasia), 30 PU (peptic ulcer)], and the control group had 40 NUD (non-ulcer dyspepsia) cases [20 Hp+, 20 Hp-]. EBV-DNA was detected by non-polymorphic EBNA-1 gene-based qPCR. EBV/EBNA-1 IgG levels were determined by quantitative and qualitative ELISA methods, respectively.
EBV-DNA positivity was 32% (8/25), 6.6% (2/30) and 5% (1/20) in GC, PU and NUD Hp (+) cases, respectively. There was a significant difference (p = 0.001) between GC (32%) and NUD Hp (+) (5%) cases in terms of EBV-DNA positivity. Mean EBV-DNA copy numbers were 6568.54 ± 20351, 30.60 ± 159.88 and 13.85 ± 61.93 for GC, PU, and NUD, respectively. In terms of the mean EBV-DNA copy number, a significant difference was found between the groups (p = 0.005). In terms of EBV/EBNA-1 IgG antibody positivity, no significant difference was found between GC and NUD cases (p = 0.248). EBV DNA positivity was found to be significant (odds ration [OR] = 26.71 (p=0.009, %95CI 2.286- 312.041) in multivariate logistic regression.
Although we had a small number of GC cases, it can be suggested that the estimated risk created by the synergistic effect based on the addition of EBV increased 26 times in the presence of Hp in GC.
幽门螺杆菌（Hp）和 Epstein-Barr 病毒（EBV）与胃癌（GC）的发病机制有关。EBV/Hp 合并感染被认为协同增加胃十二指肠疾病的发生。我们旨在确定胃十二指肠疾病中 EBV/Hp 合并感染的存在。
研究组有 68 例 Hp（+）病例[25 例 GC、13 例 IM（肠上皮化生）、30 例 PU（消化性溃疡）]，对照组有 40 例 NUD（非溃疡性消化不良）病例[20 例 Hp+、20 例 Hp-]。通过非多态性 EBNA-1 基因 qPCR 检测 EBV-DNA。分别通过定量和定性 ELISA 方法测定 EBV/EBNA-1 IgG 水平。
GC、PU 和 NUD Hp（+）病例中 EBV-DNA 阳性率分别为 32%（8/25）、6.6%（2/30）和 5%（1/20）。GC（32%）和 NUD Hp（+）（5%）病例之间 EBV-DNA 阳性率存在显著差异（p=0.001）。GC、PU 和 NUD 的 EBV-DNA 拷贝数平均值分别为 6568.54±20351、30.60±159.88 和 13.85±61.93。从平均 EBV-DNA 拷贝数来看，各组之间存在显著差异（p=0.005）。在 EBV/EBNA-1 IgG 抗体阳性方面，GC 和 NUD 病例之间无显著差异（p=0.248）。多变量逻辑回归显示 EBV DNA 阳性具有显著意义（优势比[OR]为 26.71（p=0.009，95%CI 2.286-312.041）。
尽管我们的 GC 病例数量较少，但可以推测，在 GC 中存在 Hp 的情况下，基于相加效应估计的协同作用所产生的风险增加了 26 倍。
